Paritaprevir [CAS 1216941-48-8]

Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) [1][2][3][4].

[1216941-48-8]

C40H43N7O7S

765.88

O=C([C@]1(NC([C@@]2([H])N3C[C@H](OC4=C(C=CC=C5)C5=C6C(C=CC=C6)=N4)C2)=O)[C@H](/C=C\CCCCC[C@H](NC(C7=NC=C(C)N=C7)=O)C3=O)C1)NS(=O)(C8CC8)=O

HCV; HCV Protease; SARS-CoV

99.87

DMSO : ≥ 125 mg/mL|H2O : < 0.1 mg/mL

4°C (Powder, sealed storage, away from moisture and light)

Room Temperature

H302, H315, H319, H335

H302, H315, H319, H335